Promega Corporation has announced the launch of a novel cellular target engagement technology designed to broaden the scope of the druggable proteome. The company revealed this innovation during the SLAS 2026 conference held in Madison, Wisconsin.
This technology aims to improve the identification and validation of drug targets within living cells, potentially accelerating drug discovery and development processes. By enabling more precise measurement of compound interactions with cellular proteins, the platform seeks to support researchers in uncovering new therapeutic opportunities.
**Why this matters**
Expanding the druggable proteome is critical for developing treatments for diseases with limited therapeutic options. Enhanced target engagement tools can lead to better understanding of drug mechanisms, improving the efficiency and success rate of drug development. Promega’s technology may provide researchers with more reliable data to guide the creation of new medicines.
Source: NewsData